Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.

Pharmacogenomics - 1 May 2009

Ferraldeschi Roberta, Minchell Laura J, Roberts Stephen A, Tobi Simon, Hadfield Kristen D, Blackhall Fiona H, Mullamitha Saifee, Wilson Gregory, Valle Juan, Saunders Mark, Newman William G

Abstract excerpt

AIMS: Variants in UGT1A1 have previously been associated with toxicity from irinotecan chemotherapy. We conducted a pragmatic prospective cohort study to establish the relevance of UGT1A1 variants in the prediction of severe diarrhea and neutropenia in patients with colorectal cancer receiving irinotecan in a routine clinical setting. MATERIALS & METHODS: Genotyping of UGT1A1*28 and c.-3156G>A was undertaken in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to DNA, Neoplasm

Share to Ethnicity

Share to Gastrointestinal Tract

Share to Glucuronosyltransferase

Share to Irinotecan

Source

Identifiers

PMID: 19450125
DOI: 10.2217/pgs.09.20

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.PMID 19450125Read ↗

Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.Semantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Semantic proximity Read ↗

Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.Semantic proximity Read ↗

Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.Semantic proximity Read ↗

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.Semantic proximity Read ↗

Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.Semantic proximity Read ↗

Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.Semantic proximity Read ↗

Pharmacogenetics of irinotecan toxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.